Sanofi: The drug SAR446597 has received FDA Fast Track designation
On July 16th, Sanofi announced that the U.S. Food and Drug Administration has granted SAR446597 Fast Track designation. This drug is a one-time intravitreal gene therapy for the treatment of geographic atrophy secondary to age-related macular degeneration. The Fast Track designation process is designed to facilitate the development and expedite the review of drugs that treat serious conditions and fill unmet medical needs. The FDA established this program to help patients gain earlier access to important new drugs, covering a range of serious diseases
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments